Bcal Diagnostics Ltd Total Assets
Bcal Diagnostics Ltd total assets. Based on the latest financial reports, Bcal Diagnostics Ltd (BDX) holds total assets worth AU$7.66 Million AUD (≈ $5.42 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Bcal Diagnostics Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Bcal Diagnostics Ltd (2017–2025)
Total assets of Bcal Diagnostics Ltd from 2017 to 2025. This chart illustrates how Bcal Diagnostics Ltd's total assets have evolved over time, based on quarterly financial data. See BDX stock price and chart for real-time trading data and today's change.
Bcal Diagnostics Ltd - Asset Composition Analysis
Bcal Diagnostics Ltd Total Assets Breakdown (December 2025)
Bcal Diagnostics Ltd total assets breakdown as of December 2025. Bcal Diagnostics Ltd's total assets of AU$7.66 Million consist of 53.2% current assets and 46.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 20.7% |
| Accounts Receivable | AU$2.38 Million | 31.1% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Bcal Diagnostics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Bcal Diagnostics Ltd (BDX) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bcal Diagnostics Ltd's current assets represent 53.2% of total assets in 2025, a decrease from 99.9% in 2017.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2025, down from 55.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 31.1% of total assets.
Bcal Diagnostics Ltd Competitors by Total Assets
Key competitors of Bcal Diagnostics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
India | Rs15.07 Billion |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €18.96 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
Bcal Diagnostics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.36 | 2.32 | 7.85 |
| Quick Ratio | 1.36 | 2.32 | 7.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$1.07 Million | AU$4.09 Million | AU$3.60 Million |
Bcal Diagnostics Ltd - Advanced Valuation Insights
This section examines the relationship between Bcal Diagnostics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.18 |
| Latest Market Cap to Assets Ratio | 2.38 |
| Asset Growth Rate (YoY) | -22.7% |
| Total Assets | AU$7.66 Million |
| Market Capitalization | $18.26 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Bcal Diagnostics Ltd's assets at a significant premium (2.38x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Bcal Diagnostics Ltd's assets decreased by 22.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bcal Diagnostics Ltd (2017–2025)
The table below shows the annual total assets of Bcal Diagnostics Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | AU$7.66 Million ≈ $5.42 Million |
-22.68% |
| 2024-12-31 | AU$9.91 Million ≈ $7.01 Million |
-19.21% |
| 2023-12-31 | AU$12.27 Million ≈ $8.68 Million |
+46.52% |
| 2022-12-31 | AU$8.37 Million ≈ $5.92 Million |
-20.95% |
| 2021-12-31 | AU$10.59 Million ≈ $7.49 Million |
+156.27% |
| 2020-12-31 | AU$4.13 Million ≈ $2.92 Million |
+404.23% |
| 2019-12-31 | AU$819.55K ≈ $579.89K |
+51.67% |
| 2018-12-31 | AU$540.34K ≈ $382.32K |
-3.51% |
| 2017-12-31 | AU$560.02K ≈ $396.25K |
-- |
About Bcal Diagnostics Ltd
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 an… Read more